The M367 white pill contains 10 mg of hydrocodone bitartrate and 325 mg of acetaminophen. Current DailyMed labeling describes it as a white, capsule-shaped tablet marked M367 on one side and bisected on the other. Because it contains hydrocodone, M367 is a Schedule II controlled substance.
M367 is the highest hydrocodone strength in the current M365/M366/M367 325 mg acetaminophen series: M365 contains hydrocodone 5 mg, M366 contains 7.5 mg, and M367 contains 10 mg. Readers frequently search these tablets together because they look similar and differ by a single final digit.
The imprint identifies the expected legitimate pharmaceutical product, but it cannot authenticate a pill from an unknown source. Counterfeit opioid tablets can imitate approved markings and may contain unexpected substances.
M367 Pill Identification
| Imprint | M367 |
| Drug | Hydrocodone bitartrate / acetaminophen |
| Strength | 10 mg / 325 mg |
| Color | White |
| Shape | Capsule-shaped / oblong |
| Score | Bisected on reverse |
| Route | Oral |
| Drug class | Opioid analgesic combination |
| DEA schedule | Schedule II |
| Prescription required? | Yes |
| Current label context | Mallinckrodt / SpecGx hydrocodone-acetaminophen product line |
What Is the M367 White Pill?
M367 is an immediate-release hydrocodone/acetaminophen prescription pain tablet. Hydrocodone is an opioid. Acetaminophen is a non-opioid analgesic. The combination is intended for pain severe enough to require an opioid when alternative treatments are inadequate.
“M367” is an imprint code, not the name of a separate medication. The active-drug identity is hydrocodone 10 mg with acetaminophen 325 mg.
M367 vs. M366
| M366 | Hydrocodone 7.5 mg / acetaminophen 325 mg; white oval; unscored |
| M367 | Hydrocodone 10 mg / acetaminophen 325 mg; white capsule-shaped; scored |
| Main strength difference | M367 contains 2.5 mg more hydrocodone per tablet |
| Acetaminophen | Both current products contain 325 mg |
This distinction matters because two white tablets from the same product family can contain different opioid strengths. Never infer strength from color alone.
M367 vs. IP 110
M367 and IP 110 can both identify tablets containing hydrocodone 10 mg and acetaminophen 325 mg. They are not the same imprinted product.
| M367 | White capsule-shaped tablet; M367 on one side; bisected reverse |
| IP 110 | White to off-white scored oblong biconvex tablet; IP 110 on one side; bisected reverse |
| Active ingredients | Both hydrocodone 10 mg / acetaminophen 325 mg |
| Why appearance differs | Different manufactured products can use different approved imprints and tablet designs |
How Strong Is M367?
M367 contains 10 mg hydrocodone bitartrate and 325 mg acetaminophen. The 10 mg hydrocodone strength is higher than M365 and M366, but pill strength alone does not determine how a particular patient should use the medication.
Opioid tolerance and individual medical factors strongly affect risk. A tablet that has been used safely by one patient can produce dangerous sedation or respiratory depression in another.
What Is Hydrocodone 10/325 Used For?
Current labeling indicates hydrocodone/acetaminophen for pain severe enough to require an opioid analgesic when alternative treatments are inadequate.
Use should follow the individual’s prescription. Taking someone else’s M367, using it for nonmedical effects, or increasing the amount outside prescriber instructions can substantially increase overdose risk.
How Hydrocodone Affects the Body
Hydrocodone is a full opioid agonist with activity at mu-opioid receptors. It can reduce pain but can also cause drowsiness, slowed breathing, constipation, nausea, impaired coordination, physical dependence, and addiction.
Respiratory depression is the most dangerous acute opioid effect. It can occur during prescribed use, but risk rises with excessive exposure and when opioids are combined with other depressants.
The Acetaminophen Risk in M367
Each M367 tablet also contains 325 mg acetaminophen. Too much acetaminophen can cause severe liver injury. FDA states that adults and children age 12 and older should not exceed 4,000 mg in 24 hours from all acetaminophen-containing medicines unless a clinician has set a lower limit.
The main practical risk is accidental duplication. Someone may take a hydrocodone combination tablet and then use a cold, flu, headache, or pain product that also contains acetaminophen.
Common Side Effects
- Sleepiness
- Dizziness
- Lightheadedness
- Nausea
- Vomiting
- Constipation
- Tiredness
- Headache
Patients should understand how M367 affects them before driving or doing work that requires full alertness and coordination.
M367 and Alcohol
Alcohol and hydrocodone both depress the central nervous system. Current labeling warns that combining them can cause severe drowsiness, decreased awareness, respiratory depression, coma, and death.
M367 and Xanax or Other Benzodiazepines
Alprazolam, clonazepam, diazepam, lorazepam, and other benzodiazepines can intensify opioid sedation and respiratory depression. This is a high-risk combination and should only be managed under appropriate clinical supervision.
Can You Overdose on M367?
Yes. M367 can contribute to an opioid overdose. Taking excessive quantities also creates acetaminophen poisoning risk.
Emergency signs include inability to wake, very slow or stopped breathing, gurgling or choking sounds in an unresponsive person, severe discoloration of the lips or nails, and pinpoint pupils. Call emergency services and give naloxone if available when opioid overdose is suspected.
Can M367 Get You High?
Hydrocodone can produce euphoria, relaxation, sedation, and other opioid effects. Using M367 for those effects rather than according to a prescription is misuse. Trying to intensify the effect by increasing the amount or mixing substances increases overdose risk.
Can M367 Cause Addiction?
Yes. Hydrocodone can cause opioid use disorder. Schedule II status reflects a high potential for abuse and severe physical or psychological dependence.
Physical dependence can also occur during prescribed treatment and does not by itself prove addiction. A dependent person can experience withdrawal after abrupt discontinuation.
M367 Withdrawal
Possible withdrawal symptoms include restlessness, sweating, chills, runny nose, watery eyes, yawning, muscle aches, anxiety, insomnia, abdominal cramps, nausea, vomiting, diarrhea, and increased heart rate or blood pressure.
Current opioid labeling warns against abrupt discontinuation in physically dependent patients. Any taper should be individualized.
Can M367 Be Counterfeit?
Yes. Counterfeit pills can copy the M367 imprint. An image match does not establish contents, strength, or authenticity. Pills obtained outside licensed pharmacy channels should be treated as potentially unsafe.
What if My Pharmacy M367 Looks Different?
Check the bottle and contact the pharmacist. A pharmacy may switch generic suppliers, but the dispensing record can confirm the exact product and strength. Do not assume that two white opioid tablets are interchangeable because their size or shape looks similar.
Treatment for Hydrocodone Misuse or Dependence
Someone taking more M367 than intended, using non-prescribed pills, experiencing withdrawal, or losing control over opioid use can be assessed for opioid use disorder. Medication treatment can include buprenorphine, methadone, or naltrexone when clinically appropriate.
Rehabs.Today provides directories for detox centers and residential treatment programs.
M367 vs. M365 and T257
M367 belongs to the same broad hydrocodone/acetaminophen category as M365 and T257, but their labeled opioid strengths are different. M365 and T257 contain hydrocodone 5 mg with acetaminophen 325 mg, while M367 contains hydrocodone 10 mg with acetaminophen 325 mg.
The difference is clinically meaningful even though all three can be white prescription tablets. A person should never identify hydrocodone strength from color, tablet size, or the fact that a pill “looks like Vicodin.” The full imprint and prescription label need to agree.
Why the M367 Score Line Does Not Determine Your Dose
DailyMed describes M367 as bisected on the reverse. A score line is part of the product’s appearance, but it does not tell an online reader how much hydrocodone they personally should take. Dose selection depends on the prescription, opioid tolerance, pain condition, other medicines, and the clinician’s assessment.
A score line is also useless for authenticating an illicit pill. A counterfeit tablet can be manufactured with a copied imprint and groove while containing an unexpected drug or an uneven amount of active substance.
How Long Does Hydrocodone From M367 Stay in Your System?
Current DailyMed pharmacokinetic information reports a hydrocodone half-life measured in several hours, but the half-life should not be treated as a drug-testing window. Drug metabolites can remain detectable after noticeable opioid effects have ended.
SAMHSA materials have described a typical urine detection period of about two days for hydrocodone, subject to the specific test and cutoff. Some screening assays can miss hydrocodone unless it is specifically tested for. Blood, oral-fluid, urine, and hair testing also answer different questions and have different windows.
What Makes M367 Respiratory Depression More Dangerous?
Respiratory depression means breathing becomes too slow or shallow to provide enough oxygen. The risk rises with excessive opioid exposure and with other central nervous system depressants. Alcohol, benzodiazepines, other opioids, sedating sleep medicines, and some other drugs can compound the effect.
People with significant lung disease, reduced respiratory reserve, or increased sensitivity to sedatives can also face greater danger. Severe sleepiness that progresses to difficulty waking should not be dismissed as ordinary tiredness.
Acetaminophen Poisoning Can Be Separate From Opioid Overdose
An M367 emergency does not have to look like classic opioid overdose. The acetaminophen component can cause severe liver injury after excessive exposure, and symptoms may be mild or absent early on. Someone who may have taken a dangerous amount of acetaminophen needs medical advice even if they are currently awake and breathing normally.
This is why counting only the hydrocodone milligrams misses part of the risk. Every M367 tablet also adds 325 mg of acetaminophen to the person’s total intake.
M367 During Pregnancy or Breastfeeding
Prolonged opioid exposure during pregnancy can cause neonatal opioid withdrawal syndrome. A pregnant patient should not abruptly stop a prescribed opioid without medical guidance, but opioid treatment during pregnancy also requires careful clinical planning.
Hydrocodone can pass into breast milk. Unusual infant sleepiness, limpness, poor feeding, or breathing difficulty requires prompt medical attention.
Safe Storage and Disposal
M367 should be stored securely and away from children, visitors, and anyone who might misuse prescription opioids. Leftover tablets should not be kept casually in an unlocked bathroom cabinet or shared with another person.
Authorized medication take-back programs are preferred for unused opioids when available. Follow current FDA disposal instructions if a take-back option is not readily accessible.
When Should Someone Call 911?
Call emergency services if a person who may have taken M367 cannot be awakened, is breathing abnormally, stops breathing, has severe discoloration, collapses, or is suspected of taking a counterfeit opioid. Give naloxone if available when opioid overdose is suspected.
Frequently Asked Questions About M367
What pill is M367?
M367 is hydrocodone 10 mg / acetaminophen 325 mg.
Is M367 stronger than M366?
By labeled hydrocodone strength, yes. M367 contains 10 mg versus 7.5 mg in M366.
Is M367 the same as IP 110?
They can contain the same active drugs and strength, but they are different imprinted manufactured products.
Is M367 Percocet?
No. M367 contains hydrocodone. Percocet products contain oxycodone with acetaminophen.
Is M367 Schedule II?
Yes. Hydrocodone combination products are Schedule II under current federal scheduling.
Can counterfeit pills copy M367?
Yes. Imprint copying is possible, so source matters as much as appearance.
Sources
- DailyMed: Hydrocodone Bitartrate and Acetaminophen Tablets — current labeling, strengths, appearance, warnings, pharmacokinetics and Schedule II status.
- Drug Enforcement Administration: Drug Scheduling — current federal Schedule II classification for hydrocodone combination products and oxycodone.
- U.S. Food and Drug Administration: Acetaminophen — total daily acetaminophen safety information.
- U.S. Food and Drug Administration: Counterfeit Medicine — counterfeit prescription-drug risks.
- Centers for Disease Control and Prevention: Overdose Prevention — opioid overdose recognition and naloxone information.
- SAMHSA: Substance Use Treatment Options — evidence-based opioid use disorder treatment options.
About This Article
Editorial standard
Rehabs.Today resource articles are written for educational and treatment-navigation purposes. For medical and drug-safety claims, we prioritize current primary or authoritative references such as FDA and DailyMed labeling, CDC, SAMHSA, NIH/NCBI resources, and peer-reviewed research when appropriate. Important limitations, uncertainty, and differences between population-level evidence and individual medical advice are stated where they matter.
How to use this information
This article provides general educational information. It is not a diagnosis, prescription, personalized taper, or substitute for advice from a physician, pharmacist, or other qualified healthcare professional. Do not start, stop, combine, or change a prescribed medication solely because of information on this page.
Emergency information
If someone cannot be awakened, is breathing slowly or abnormally, or may be experiencing an opioid overdose, seek emergency medical help immediately and give naloxone if it is available.
Treatment-directory transparency
Some Rehabs.Today articles link to treatment directories and provider resources. Those links are for navigation and do not replace independent medical assessment. Medical claims in the article should be evaluated from the cited evidence, not from whether a treatment provider is linked.